Cryoport (CYRX) Proxy filing summary

Executive summary

• Achieved $176.2 million in 2025 revenue, a 12% year-over-year increase, driven by growth in Cell & Gene Therapy (CGT) and Life Sciences Services, with commercial CGT revenue up 29% and clinical trial revenue up 14%.

• Supported a record 760 clinical trials and 20 commercial therapies globally, representing about 70% of all CGT-industry clinical trials.

• Expanded global footprint with new supply chain centers in Paris and Santa Ana, and expanded BioServices in Belgium.

• Formed strategic partnerships with DHL, Cardinal Health, and Parexel, and launched the Enterprise Technology Group to drive digital transformation and AI integration.

• Forecasting 2026 revenue of $190–$194 million, with expectations for nine new therapy approvals and thirteen BLA/MAA filings.

Voting matters and shareholder proposals

• Election of six directors to serve until the 2027 Annual Meeting.

• Ratification of Deloitte & Touche LLP as independent auditor for 2026.

• Advisory vote on executive compensation (say-on-pay).

• Approval of an amendment to the 2018 Omnibus Equity Incentive Plan to increase authorized shares.

Board of directors and corporate governance

• Board consists of six directors, five of whom are independent; annual elections with no staggered board.

• Committees include Audit, Compensation, Nomination and Governance, and Science and Technology, all with independent chairs.

• Board diversity matrix provided; board skills include strategic thinking, financial literacy, and life sciences expertise.

• Lead Director role established for independent oversight.

• Board met five times in 2025; all directors attended at least 75% of meetings.